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ABSTRACT 
The last decade has witnessed a rapid growth in the development of protein pharmaceuticals for 
diagnostic and therapeutic purposes. The biopharmaceutical industry increasingly demands 
thorough characterization of protein conformation and conformational dynamics to ensure 
product quality and consistency. Here we present a chromatography-based method that is able to 
characterize protein conformation and conformational dynamics at peptide level resolution in a 
high-throughput manner. The surface lysine residues of the protein were labeled with a 
fluorescent dye prior to trypsin and Glu-C digestion.  The resulting peptide maps were monitored 
by fluorescence detection and the peak areas of the respective peptides were normalized to 
protein concentration. The normalized fluorescence peak area for a specific peptide represents 
the individual lysine solvent accessibility.  A higher normalized fluorescence peak area indicates 
higher solvent accessibility at a specific site. The identity of the peak of interested was 
determined by LC-MS/MS analysis. We first demonstrated this method is suitable for probing 
protein surface/conformation by studying the effect of deglycosylation on a recombinant 
monoclonal antibody (mAb), IgG 1. The results from this method were consistent with previous 
results obtained by H/D-exchange. We then applied our method to study the interaction of the 
mAb with a common excipient, polysorbate-20 (PS-20). The interaction between PS-20 and the 
mAb was generally weak. The presence of PS-20 increased the fluorescent labeling of several 
lysine residues on the mAb. These lysine residues localized near the protein domains of 
relatively high hydrophobicity. This result provides a first insight into PS-20-mAb interaction at 
peptide level resolution.  
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INTRODUCTION 
Proteins provide a wide array of functions in living organisms and are involved, e.g., in active 
transport processes, metabolism and immunity. Protein function is determined by protein 
structure and conformational dynamics where protein structure is defined as primary, secondary, 
tertiary and quaternary structure. The primary structure involves the amino acid sequence and its 
post-translational modifications such as, e.g., oxidation, deamidation and phosphorylation
1
. 
Higher-order structures of proteins depend on the conformation of local substructures, the global 
structures of protein molecules and the assembly of multi-subunit proteins
2
. Importantly, proteins 
are dynamic because either the entire molecule and/or its local substructures may open, close and 
tumble on various time scales
3
. In the biopharmaceutical industry, the conformation and 
conformational dynamics of proteins are important for product quality and comparability
3-6
. 
Therapeutic protein can be produced through multiple means, such as recombinant, purified or 
the combination of the two.  As a pharmaceutical product, the quality of therapeutic proteins is 
strictly controlled and monitored. The control system of each therapeutic protein is comprised of 
many assays that ensure the whole production, purification, formulation and filling processes are 
performing as expected.  The quality of therapeutic protein is defined in many facets. The quality 
attributes that affect the activity and/or safety of the therapeutic protein are called critical quality 
attributes (CQAs)
7,8
.  Protein higher-order structure can be one of or closely linked to the CQAs. 
For example, scrambled disulfide bonds can lead to altered higher-order structure that may affect 
protein’s safety and efficacy profile, thus is usually a CQA
9,10
. Scrambled disulfide bond can 
usually be detected by LC-MS/MS that requires method development for each specific molecule. 
However, a method that directly detects higher-order structure change regardless of the source is 
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more universal that eliminates the need of method development for each modification and 
molecule.  
Studying the dynamics and higher order structure of proteins also offers insight into product 
quality consistency, such as batch-to-batch consistency and stability
3,11
. The information about 
the conformation and conformational dynamics of proteins will also assist in determining 
whether a variant would have safety or efficacy issues. 
The characterization of conformation and conformational dynamics of proteins usually requires 
sophisticated methodologies such as nuclear magnetic resonance spectroscopy (NMR) 
12,13
, X-
ray crystallography
14,15
, Fourier transform infrared spectroscopy (FT-IR)
16-18
 and circular 
dichroism (CD)spectroscopy
19,20
. Among these, NMR and X-ray crystallography offer structural 
determination and excellent resolution but involve intensive sample preparation, analysis and 
data interpretation
21
. NMR usually requires isotopically labeled proteins in relatively large 
quantity while X-ray crystallography requires crystallized protein that is not always available. 
The other two techniques (FT-IR and CD) do not have such a high requirement on sample but 
lack residue-level structural information
21
.  
In most of the situations encountered in the biopharmaceutical industry, only structural 
comparison rather than structural determination is needed
22,23
. Several analytical methodologies 
have been developed to serve that increasing demand, including hydrogen/deuterium exchange 
mass spectrometry (H/DX-MS)
22,24-27
 and chemical footprinting methods
25,28-32
. Both of these 
methodologies can offer peptide or residue level resolution for evaluating structural and dynamic 
differences between two samples. However, these methods require specialized equipment and 
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high-resolution MS. Additionally, the data analysis is often time-consuming (1-2 days per 
sample
22
) and requires specialized software.  
Here we describe an HPLC-based technology to characterize the conformation and 
conformational dynamics of a protein. The method can be used in a high throughput manner and 
does not require specialized software. This technology involves labeling the solvent-accessible 
lysines with a fluorescent dye in buffer and then enzymatically digesting the sample. The peptide 
maps are monitored both by UV- and fluorescence detection, and the fluorescence peak area 
normalized to protein concentration.  The normalized fluorescence peak area corresponds to the 
local solvent accessibility of a specific lysine residue, and can thus, be used to compare the 
conformation and dynamics of two protein.  We demonstrated the utility of this method by 
assessing the effect of deglycosylation on a recombinant mAb (IgG1). Our results are largely 
consistent with previous conformational studies based on H/DX-MS. We then applied this 
method to study the interaction between mAb and polysorbate 20 sorbitan monolaureate (PS-20). 
PS-20 is a widely used excipient in therapeutic protein formulations to reduce protein 
aggregation during production and shipping 
33
 
34
 
35
 
36
 and to reduce protein adsorption on glass 
surfaces 
37
.  Its interaction with protein had been studied by means of CD spectroscopy, 
isothermal titration calorimetry (ITC) and tryptophan fluorescence
 42,43
. The methodology 
described here offers an opportunity to gain insight into the interactions between a mAb and PS-
20 on a peptide level for the first time.  
Overall, the results from this study suggest that this protein surface lysine fluorescent labeling 
method is capable of detecting protein conformation and dynamics differences at the peptide 
level without the requirement of sophisticated instrumentation or specialized software. This 
methodology is, therefore, amenable for high throughput analysis. 
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EXPERIMENTAL SECTION 
Materials 
Alexa Fluor® 350 SE was purchased from Life Technologies® (Carlsbad, CA). Dithiothreitol 
(DTT), Tris (2-carboxyethyl)phosphine hydrochloride (TCEP-HCl),  iodoacetic acid sodium salt 
(IAA), guanidine hydrochloride, acetonitrile (ACN), methanol, polysorbate-20 (PS-20) and 
trifluoroacetic acid (TFA) were obtained from Sigma-Aldrich® (St. Louis, MO).  PNGase F was 
purchased from Prozyme® (San Diego, CA). Trypsin, sequencing grade was acquired from 
Promega® (Madison, WI) while Glu-C was obtained from Roche® Diagnostics (Indianapolis, 
IN). The monoclonal antibody 1 (mAb 1) used in the experiments was generated at Genentech, 
Inc..  
Protein denaturation, reduction and digestion 
Labeled protein samples were diluted 6-fold using 8 M guanidine-HCl. The pH of the solution 
was adjusted to 7.5 with 1M Tris prior to the addition of 12 µl of 1 M DTT to each sample to 
reduce the disulfide bonds; the samples were incubated at 37
°
C for 1 hr. After reduction by DTT, 
15 µl of 2.9 M IAA were added to each sample to alkylate free cysteine residues. The remaining 
IAA was quenched by addition of 30 µl of 1 M DTT to each sample after an incubation period of 
15 min at 37
°
C. The samples were then buffer exchanged into 10 mM phosphate buffer, pH 7.5, 
employing NAP-5 columns (GE healthcare lifesciences, Piscataway, NJ ). Subsequently, a stock 
solution of 1 mg/ml Glu-C was added to each sample to acquire a final mAb1:Glu-C ratio of 40 : 
1. The samples were incubated at room temperature for 18 hr. After completion of the Glu-C 
digestion, a stock solution of 1 mg/ml trypsin was added to samples to attain an mAb1:trypsin 
ratio of 40: 1. The samples were then incubated at 37
°
C for 2 hr. The digestion was quenched by 
addition of 20 µl of 10% TFA.  
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Deglycosylation 
The mAb1 was buffer exchanged and diluted to 5 mg/mL with 10 mM phosphate buffer, pH 7.5. 
Approximately 20 mU PNGase F were added to the mAb1 solution and the samples incubated at 
37
0
C overnight. A control sample was prepared by incubation of mAb-1 at 37
°
C overnight in the 
absence of PNGase F.  
Preparation of samples containing polysorbate-20 
A stock solution of PS-20 was prepared at 10% (w/w) in 10 mM phosphate buffer, pH 7.5.  
Different volumes of the PS-20 stock solution were added to solutions of 5 mg/mL mAb1 in 10 
mM phosphate buffer, pH 7.5, so that the final PS-20 levels were 0.01%, 0.05%, 0.1% and 0.5% 
(w/v).  The PS-20 containing samples were incubated at room temperature for 1 hr before they 
were subjected to surface lysine fluorescent labeling followed by denaturation, reduction and 
digestion as described above.  
Reverse-phase HPLC analysis of dye hydrolysis 
An Agilent® 1290 HPLC system equipped with a fluorescence detector was connected to an 
Agilent® Poroshell 120 SB-C18 column (4.6 x 75 mm, 2.7 μm, pore size 120 Å). The mobile 
phases were methanol (A) and water (B). A linear gradient changed the content of mobile phase 
B from 20-100% within 5 min. The flow rate was 1 ml/min and the injection volume was 1 μL, 
with the column temperature set to 45 
°
C. The excitation and emission wavelengths were 350 nm 
and 490 nm. 
Size-exclusion HPLC analysis  
A Waters® 2796 HPLC system equipped with a UV detector was connected to a TSK 
G3000SWXL column (7.8 x 300 mm; TOSOHAAS®). The mobile phase was 0.2 M potassium 
phosphate buffer, pH 6.2. The sample was analyzed under isocratic conditions at a flow rate of 
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0.5 mL/min for 30 min. The injection volume was 10 µL and the column temperature was at 
ambient.  
Reverse-phase HPLC conditions for peptide mapping 
A Waters
®
 2796 HPLC system or equivalent HPLC systems equipped with UV and fluorescent 
detectors was connected to a Phenomenex Luna
®
 C18 column ( 2.1 x 250 mm, 3.5 μm, 300 Å). 
The mobile phases were 0.1 % TFA in water (A) and 0.08 % TFA in acetonitrile (B). The 
column was conditioned with 1% B for 3 min. A linear gradient program consisted of the 
following steps:  3 min, 1% B; 13 min, 10% B; 90 min, 30% B; 153 min 45% B; 160 min, 95% 
B; 165 min, 45% B; 168 min, 1% B; 180 min, 1% B.  The flow rate was 0.25 ml/min and the 
injection volume was 50 μL. The oven temperature was kept at 60 
°
C. The excitation and 
emission wavelengths used were 350 nm and 490 nm for Alexa Fluor® 350. 
HPLC-MS/MS analysis 
HPLC-MS/MS data were acquired on an Orbitrap® XL instrument (Thermo Scientific, Waltham, 
MA) interfaced with an Agilent® 1200 HPLC system. The chromatography conditions applied 
were the same as described above for peptide mapping.  The MS data were acquired over the 
range between 500 and 2000 m/z. The ions with top 5 abundances were selected for MS/MS 
fragmentation analysis.  
MS analysis of non-digested (intact) protein 
The molecular weights of protein samples were measured by an Agilent® 6210 Series HPLC-
Chip/TOF MS system. For intact mass measurement, the sample was diluted to 1 mg/mL by 
mobile phase A (see below). For mass measurement after disulfide reduction, the samples were 
incubated with 1 M TCEP-HCl for 10 min at room temperature before dilution to 1 mg/mL with 
- 7 - 
 
mobile phase A. The HPLC-chip consisted of a desalting column and a C18 analytical column. A 
gradient was delivered at 0.4 μL /min flow rate using 0.1% formic acid in water (mobile phase A) 
and 0.1% formic acid in acetonitrile (mobile phase B). A linear gradient was run from 10% B to 
70% B within 8 min. A total of 5 ng protein was loaded onto the column and analyzed in the 
range of 500-3000 m/z. 
MS data analysis 
MS data for intact and reduced mAb1 were processed and deconvoluted using the MassHunter
®
 
Workstation B.06.00 (Agilent
®
). The deconvolution mass range was 130k-160k Da for intact 
protein samples and 40k-70k Da for reduced protein samples. The HPLC-MS/MS data were 
analyzed by ProteomeDiscoverer 3.1 
®
 (Thermo
®
). A fixed modification of carboxymethylation 
and customized optional modification of Alexa Fluore® 350 were included. Glu-C and trypsin 
combination enzymes were selected with up to two missed cleavages.  
 
Surface Lysine Fluorescent Labeling 
Monoclonal antibody-1 was buffer exchanged into 10 mM phosphate buffer, pH 7.5, to a final 
concentration of 5 mg/mL. A stock solution of 70 mM Alexa Fluor 350 SE in water was 
prepared, and added to the mAB1 samples such that the final ratio of dye:protein was 100:1.  The 
samples were incubated at 37 
°
C for 1-5 min. At each time point, 100 µL of sample were 
withdrawn from the reaction tube and the derivatization reaction quenched with 20 µL 10% TFA.  
Labeled samples were then denatured and digested according to the protein digestion protocol 
described below. 
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RESULTS AND DISCUSSION 
Method Development and Optimization for Protein Surface Lysine Fluorescent Labeling 
 
Labeling efficiency 
A commercially available fluorescent dye, Alexa Fluor® 350 SE (succinimidyl ester) was 
selected as the lysine labeling reagent. It offers a high fluorescence quantum yield and good 
water solubility, and presents a succinimidyl ester function that selectively reacts with primary 
amines. In order to optimize the conditions for protein surface lysine fluorescent labeling, we 
studied the effect of dye-to-protein ratio and reaction time on the labeling of mAb1. The goal 
was to minimize the reaction time to reduce potential structural changes induced by the labeling 
reaction, while achieving high labeling coverage at the same time.  
It is known that dye hydrolysis may compete with lysine labeling
38
. Therefore, we first measured 
the rate of hydrolysis using a chromatography-based method. The dye was subjected to the same 
reaction conditions as encountered during the labeling reaction but without the presence of 
mAb1. The reaction mixture was sampled every 10 min by a HPLC auto-sampler for the duration 
of 120 min. The results (data not shown) showed that the hydrolysis reaction followed pseudo-
first order kinetics, where <5% dye in the ester form remained after 120 min. 
We then subjected mAb1 to reaction with Alexa Fluor 350 SE at dye-to-protein ratios of 40:1 
and 100:1 and 37
°
C for 1-60 minutes.  Aliquots of 100 µL were withdrawn from the reaction 
mixtures at 1, 2, 3, 5, 10, 20, 30 and 60 min and quenched with 10 µL of 10% TFA. The progress 
of lysine labeling was monitored at both dye-to-protein ratios by ESI-MS analysis. The labeling 
of one lysine residue gives rise to a mass shift of +295.01 Da. The relative abundance of protein 
species containing different numbers of labeled lysine residues was quantified through the peak 
heights of the respective MS signals. Interestingly, no apparent differences in average labeling 
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efficiencies were observed for the heavy chains (HC) of both the glycosylated (native) and 
decglycoslyated mAb1. The average number of labels per chain was calculated by multiplying 
the number of labels of a given peak by its % abundance in all detected peaks. The average 
number of labels on each chain at 1-60 min reaction time with 40:1 and 100:1 dye-to-protein 
ratios is shown in Figure 1. Figures 1a and 1b show that the average number of labels on the 
light chain (LC) and HC increases with reaction time for both dye-to-protein ratios. Higher 
labeling yields were detected for a dye-to-protein ratio of 100:1 compared to that of 40:1. The 
average number of labels incorporated into mAb1 increased for the entire 60 min of reaction 
time when the dye-to-protein ratio was 100:1 while the average number of labels leveled off at 
ca.30 min reaction time when the dye-to-protein ratio was 40:1. Apparently, the fluorescent dye 
available for reaction with lysine was depleted at ca.30 minutes when the dye-to-protein ratio 
was 40:1, consistent with the kinetics for the competitive hydrolysis reaction. At this point, the 
total number of dye reacted with mAb1 can be calculated from Figures 1a and 1b as 9 labels 
incorporated per molecule of mAb1. Therefore, when the dye is present at a 40:1 dye-to-protein 
ratio, the fraction of dye consumed via labeling within 30 minutes is ca. 40%.  When the 
competitive hydrolysis reaction is taken into account, virtually no dye in the ester form is 
available after 30 min.   
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Figure 1. Average number of labels observed at different reaction times for protein-to-dye ratios 
of 1:40 and 1:100 for mAb-1. The results for light chain (LC) and heavy chain (HC) are shown 
in 1a and 1b, respectively. The error bar shows the RSD% values from three experiments. 
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On the other hand, when the dye-to-protein ratio was 100:1, there is sufficient dye available for 
reaction with the protein for the entire 60 min of reaction time. Therefore, a target dye-to-protein 
ratio of 100:1 was chosen in the final method, but it was less critical as long as the ratio remained 
the same for samples in comparability experiments. 
Minimization of labeling time 
The fraction of labeled lysine per molecule needs to be controlled at a low level in order to 
1.minimize the structural perturbation introduced by the labeling reaction itself, and 2. be able to 
differentiate the lysines with different solvent accessibilities. For reaction times less than 5 min, 
<10% of total lysine residues were labeled on each mAb1 molecule. Additionally, the average 
number of labels incorporated increased at a rather similar rate for both dye-to-protein ratio of 
40:1 and 100:1 at short reaction times and the labeling time course results are less sensitive to an 
accurate measurement of protein concentration within this short reaction time frame. Therefore, a 
total reaction time of 5 min with 1 min intervals for sampling was selected as the experimental 
conditions for protein surface lysine labeling.  
Peptide mapping 
The derivatized lysine residues can no longer be cleaved by trypsin. As a result, longer peptides 
and reduced sequence coverage can be expected if the digestion were to be performed with 
trypsin alone. Therefore, a combination of Glu-C and trypsin was employed for the digestion 
step. The extent of mAb1 digestion was measured by examining a partially digested peptide, 
which eluted at the end of the chromatogram and was recorded during peptide mapping. With the 
digestion protocol described in the Methods section (see above), the partially digested peptide 
accounted for <5% of the total peak area (data not shown), indicating rather complete digestion. 
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The sample digested with Glu-C and trypsin was then analyzed by HPLC-MS/MS and a >90% 
sequence coverage was achieved. All lysine-containing peptides were observed with high 
confidence.  A list of the identified lysine-containing peptides found in fluorescently labeled 
mAb1 can be found in the supplementary data (Table 1). All but two lysine residues were 
fluorescently labeled. The two peptides, LC 103-106 and LC 167-169 contained unreacted lysine 
residues. This may be caused by a lower solvent accessibility, salt bridges with adjacent amino 
acid residues, or higher than usual pKa values of the side chain amino groups. The exact reason 
for the absence of labeling at these two lysines is currently unknown; however, this feature was 
consistently observed in all our experiments with the mAb1. Importantly, our experimental 
conditions ensured that, only a single lysine was labeled in all peptides containing multiple 
lysine residues  (Table 1). Moreover, it appeared that lysine residues at different positions within 
these peptides were labeled to a similar extent. Peptides containing multiple lysine residues but 
with different singly labeled lysine were not resolved by our chromatographic method; however, 
labeling of the individual lysine residues was confirmed by MS/MS analysis (data not shown).  
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Table 1. List of identified lysine-containing peptide found in fluorescently labeled mAb-1. The 
calculated mass, observed mass and mass difference were shown in the table. The observed 
labeling site(s) and additional modifications were also shown in the table. HC: heavy chain; LC: 
light chain. 
Peptide 
Calculated 
mass/Da 
Observed 
mass/Da 
Mass 
difference 
(ppm) 
Labeling site 
Additional 
modification 
Peptides with labeled lysine identified 
HC 39-46 1093.44 1093.44 1.6 HC 43  
HC 47-65 2439.05 2439.05 2.9 HC 63 or HC 65  
HC 68-76 1318.57 1318.58 2.4 HC 74  
HC 75-87 1861.83 1861.84 2.5 HC 76  
HC 127-152 2784.30 2784.30 0.2 HC 38 carboxymethyl 
HC 227-238 1574.58 1574.59 3.1 HC 227 
 
HC 239-253 1890.96 1890.96 2.0 HC 51 or HC 53  
HC 278-288 1649.67 1649.67 0.3 HC 80 
 
HC 280-293 1971.81 1971.80 -4.9 HC 93 
 
HC 289-297 1344.62 1344.63 1.3 HC 93 or HC 95 
 
HC 307-323 2231.06 2231.06 2.2 HC 309 or HC 310 carboxymethyl 
HC 324-331 1321.54 1321.53 -2.2 HC 25 carboxymethyl 
HC 328-338 1432.65 1432.66 2.5 HC 433 
 
HC 332-343 1561.77 1561.77 2.6 HC 339 or HC 343 
 
HC 363-375 1816.81 1816.81 -0.5 HC 365 or HC 375 carboxymethyl 
HC 394-406 1757.71 1757.72 3.7 HC 397 
 
HC 415-421 1112.48 1112.48 1.2 HC 419 
 
LC 25-44 2574.12 2574.14 6.2 
LC 38 or LC 41 or 
LC 44 
 
LC 39-60 2514.25 2514.26 6.8 LC 41 or LC 44  
LC 42-60 2232.09 2232.09 1.3 LC 44  
LC 81-104 3166.27 3166.28 2.4 LC 102 carboxymethyl 
LC 108-125 2240.03 2240.04 3.0 LC 125 
 
LC 123-142 2591.17 2591.18 4.9 LC 125 carboxymethyl 
LC 143-148 1053.46 1053.46 0.3 LC 144 
 
LC 145-160 2096.87 2096.88 2.4 LC 148 
 
LC 169-184 1982.83 1982.83 0.8 LC 182 
 
LC 170-186 2159.91 2159.91 1.8 LC 182 
 
LC 187-194 1329.50 1329.50 -0.3 LC 187 or LC 189 carboxymethyl 
LC 195-210 2051.94 2051.94 3.5 LC 206 
 
Peptides with unlabeled lysine identified 
LC 103-106 487.30 487.30 1.5   
LC 167-169 1716.88 1716.88 0.4 
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The UV-trace of fluorescently labeled mAb 1 peptide map shows significantly more peaks than 
usually expected in a typical peptide map of a monoclonal antibody. The increased number of 
peaks is due to (i) the presence of peptides with and without lysine labeling, (ii) the effect of 
lysine-labeling on tryptic digestion, and (iii) missed cleavages mainly by Glu-C. Not all peaks 
were baseline-resolved and the characterization of all peaks would take a significant amount of 
time. On the other hand, observe the map with the fluorescent detector offers a much cleaner 
view, showing only the peptides that contain lysine residues labeled with the fluorescent dye. 
These peaks can be identified by mass spectrometric analysis and the corresponding UV peaks 
can then be identified from their same retention times. The fluorescence peak area can also be 
automatically measured as all fluorescence peaks are baseline-resolved with good signal-to-noise 
ratio. A Typical peptide maps of mAb1 with labeled lysines can be found in supplementary data 
(Figure 2a (UV-detection at 214 nm) and Figure 2b (fluorescence exc em 
= 490nm)). Only the retention time window from 42 to 67 min is displayed in these figures.  
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Figure 2. Typical chromatograms of a mAb1 tryptic + Glu-C digest observed monitored by UV 
(a) and fluorescence (b) detection. The chromatogram was zoomed-in to retention times between 
42 and 67 min. The UV detector wavelength was 214 nm while the excitation and emission 
wavelengths for the fluorescent detector were set at 350nm and 490 nm, respectively.  
Relative quantitation 
Since there are multiple steps involved in sample preparation, the degrees of recoveries of the 
different steps are reflected in the fluorescence peak area (AFR). The direct measurement of 
protein concentration after lysine labeling was not feasible due to the absorbance of the 
fluorescent dye at 280 nm. Therefore, the UV peak areas recorded at 214 nm of three non-lysine-
containing peptides were used to determine protein concentration in each sample. As these 
peptides do not contain lysine, their UV absorption is not contaminated by dye absorption, and is 
proportional to their abundance. Additionally, these peaks are well-resolved from adjacent peaks. 
An arbitrary protein concentration can be assigned to one of the samples and the protein 
concentrations of all other samples can be normalized to this value. The UV peak area (AUV) was 
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measured for each of the three peptides and the ratio of AFR and AUV was calculated. The average 
value of this ratio was used to normalize fluorescence peak area. The normalized fluorescence 
peak area (A
0
FR) was used to represent the fluorescent labeling level of that peptide. The term 
A
0
FR and fluorescent labeling level will be used interchangeably in this paper. The calculation of 
A
0
FR for peak I follows the expression below: 
𝐴𝐹𝑅
0
𝑖
=
𝐴𝐹𝑅𝑖
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 
𝐴𝐹𝑅
𝐴𝑈𝑉
𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡ℎ𝑟𝑒𝑒 𝑛𝑜𝑛 − 𝑙𝑦𝑠𝑖𝑛𝑒 𝑐𝑜𝑛𝑡𝑎𝑖𝑛𝑖𝑛𝑔 𝑝𝑒𝑝𝑡𝑖𝑑𝑒𝑠
 
The reproducibility of this method was assessed with triplicate experiments. The normalized 
fluorescence peak areas were also calculated and the RSD% value for these three experiments 
were <10%. The level of missed cleavages was carefully examined both qualitatively and 
quantitatively for each experiment and was deemed constant.   
Structural Changes Induced by Deglycosylation 
Previous NMR and H/DX-MS
24,39
 experiments have revealed that IgG1 undergoes multiple 
structural changes upon deglycosylation. These structural changes are mainly located in the CH2 
and CH3 domains of the Fc region. The NMR method demonstrated that residues that showed 
chemical shift differences were located on the opposite side of the glycosylation site in the CH2 
and CH3 domains. Instead, the HDX-MS method revealed a more wide-spread difference in H/D 
exchange throughout the Fc region. The chemical shift differences observed by NMR and 
differences in H/D exchange rates are both indicators of protein structural changes. Since this 
fluorescent labeling method is set up to experimentally access the solvent accessibility of surface 
lysines, it should be able to reveal structural differences between native and deglycosylated 
mAb1.  
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The mAb1 used in the present study is an IgG1 molecule with N-glycosylation at N305 on both 
heavy chains. To compare the structural changes upon deglycosylation, mAb1 was subjected to 
PNGase F treatment as described above. The complete removal of the N-glycan was confirmed 
by ESI-MS analysis (data not shown). It was reported that the removal of N-glycans can 
sometimes lead to dimerization
40,41
. Therefore, the levels of dimers for both native and 
deglycosylated mAb1 were monitored by size-exclusion chromatography (data not shown). The 
dimer levels in both samples were comparable, 0.7% for native and 0.8% for deglycosylated 
mAb1, demonstrating that the removal of N-glycan from mAb1 did not significantly increase 
dimer levels. Subsequently, both native and deglycosylated mAb1 were subjected to 
fluorescence labeling with Alexa Fluor 350 SE and peptide mapping. Chromatograms of the 
digested samples were monitored both by UV and fluorescence detection, and individual peaks 
were analyzed by HPLC-MS/MS. Normalized fluorescence peak areas (A
0
FR) were calculated 
using the formula described above.  
The A
0
FR for labeled native and deglycosylated mAb1 after 5 min reaction time are shown in a 
mirror plot in Figure 3. Only the peptides monitored by fluorescence detection are plotted and 
consecutively numbered according to their retention times. The normalized fluorescence peak 
areas are different for lysine residues at different locations on the mAb1, indicating that they 
exhibit different reactivity with the fluorescent dye. By comparing the normalized fluorescence 
peak areas of native and deglycosylated mAb1, we can identify the lysine-containing peptides 
that experience structural change induced by deglycosylation. A visual comparison of the 
normalized fluorescence peak areas in Figure 3 reveals a major difference of the labeling 
efficiency for peptide 21.  
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Figure 3. Mirror plot of the lysine-containing peptides from native (upper) and deglycosylated 
(lower) mAb1 with derivatized by surface lysine fluorescence labeling. Labeling was performed 
at a protein-to-dye ratio of 1:100 with a labeling time of 5 min. The fluorescence peak area of 
each peak was normalized to the protein concentration of the sample. The peptides are numbered 
according to their retention times. The error bar shows the RSD% values from three experiments. 
 
The A
0
FR of the deglycosylated sample was significantly larger than that of native sample for this 
peptide. To analyze for minor differences, the %A
0
FR difference for each peptide i can be 
calculated based on equation (1): 
%A𝐹𝑅
0  𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝑖 =
𝐴𝐹𝑅,𝑑𝑒𝑔𝑙𝑦𝑐𝑜𝑠𝑦𝑙𝑎𝑡𝑒𝑑,𝑖
0 −𝐴𝐹𝑅,𝑛𝑎𝑡𝑖𝑣𝑒,𝑖
0
𝐴𝐹𝑅,𝑛𝑎𝑡𝑖𝑣𝑒,𝑖
0 × 100%              (1) 
The %A
0
FR difference for each fluorescently labeled peptide is displayed in Figure 4. The two 
bold lines in Figure 4 indicate a ±3RSD% difference. A percent A
0
FR difference greater than 
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±3RSD% was considered significant. The difference for most of the peptides was within assay 
variability, indicating limited structural changes upon deglycosylation. This observation is 
qualitatively consistent with the published NMR and HDX-MS data on IgG1. Only a few 
peptides showed a %A
0
FR difference greater than 3RSD%. 
 
 
  
Figure 4. Bar chart showing the percent difference between normalized fluorescence peak area 
of lysine-containing peptides from native and deglycosylated mAb1 derivatized by surface lysine 
fluorescent labeling. The peptides are numbered according to their retention times. Labeling was 
performed at a protein-to-dye ratio of 1:100 with a labeling time of 5 min. The ± 3 RSD% levels 
of this experiment are marked with a bold line. Percent difference greater than 3 RSD% was 
deemed as significant. The error bar shows the RSD% values from three experiments. 
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The locations of these peptides on a mAb1 homology structure are displayed in Figure 5. 
Among these, peptide 21 showed the most significant change in A
0
FR. The locations of lysines 
and the N-glycosylation site are color-coded in Figure 5, while the glycan structures are not 
shown. The labeling efficiency for most of the lysine residues remained unchanged upon 
deglycosylation. The lysine residues with an increased labeling efficiency after deglycosylation 
are K251, K253, K365 and K375, all of which are located on the HC of mAb1. Peptide 21, 
containing K251 and K253, showed a ca.4-fold increase of lysine labeling after deglycosylation. 
These two lysine residue are located in the CH2 domain of mAb1, for which NMR and H/DX-
MS revealed increased solvent accessibility upon deglycosylation. On the other hand, the 
labeling efficiency of K365 (peptides 28 and 29) and K375 (peptides 12 and 31) increased only 
moderately (ca. 30%).  These two lysine residues are located in the CH3 domain of 
mAb1.H/DX-MS analysis revealed a similar result while NMR analysis showed no significant 
difference of solvent accessibility difference in for this region. On the LC, K125 (peptides 20 
and 35) suffered a ca.30% reduction of labeling upon deglycosylation. This peptide is located 
relatively far away from the N-glycosylation site showing that deglycosylation may induce long-
distance structural or dynamic changes. Interestingly, the two K125 residues on both light chains 
are located in close distance from each other (Figure 6). These lysine residues are also located 
next to acidic residues, D and E, which are negatively charged under our experimental conditions 
(pH 7.5). Upon deglycosylation, a slight structural change could result in increased electrostatic 
interactions between positively charged K and negatively charged D and E. An increased 
electrostatic interaction may shorten the distance between the two halves of the antibody, or slow 
down the conformational dynamics (e.g. opening and closing of this local domain). As a result, 
the labeling efficiency of these two lysine residues can decrease upon deglycosylation. The exact 
-21- 
 
cause for the reduced labeling of K125 was out of the scope of this work and was not further 
pursued.   
 
 
Figure 5. Homology structure of mAb1 showing the lysine residues and N-glycosylation site 
(side view). The lysine residues with an unchanged level of fluorescence labeling upon 
deglycosylation are colored blue, lysine residues with increased levels of fluorescence labeling 
upon deglycosylation are colored green, while lysine residues with decreased levels of 
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fluorescence labeling upon deglycosylation are colored yellow. The N-glycosylation site is 
colored red. The glycan structures are not shown. Time courses showing peptides with 
differences in fluorescence labeling are shown on the bottom.  
 
 
Figure 6. Homology structure of mAb1 showing the lysine residues with decreased levels of 
fluorescent labeling (HC K125) upon deglycosylation (top view). Neighboring acidic amino 
acids (E and D) are colored cyan. These residues are shown as spheres. Otherwise, the color 
scheme is the same as in Figure 5.   
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The locations of lysine residues with significant differences in labeling efficiency represent 
locations where deglycosylation significantly changes the reactivity with the labeling reagent. 
This change of reactivity most likely correlates with increased solvent accessibility. Our results 
generally agree with published data in that only limited structural change is observed upon 
deglycosylation of IgG1. The small differences between the exact locations of structural changes 
at the amino acid level between our data and the work of others may result from the use of 
different techniques (labeling of K vs. NMR and H/DX-MS), a different sequence of our mAb1 
and different experimental conditions (pH). In addition, surface lysine labeling monitors 
structural differences experienced by the amino acid side chain rather than the backbone, which 
is monitored by H/DX-MS.  
The new methodology described here is able to identify structural changes at the peptide level. 
The main advantage of our method is the short sample preparation protocol and a straight-
forward data analysis. Data analysis is based on chromatographic peak areas with good 
resolution and S/N. Therefore, our method can be applied in a high throughput manner with no 
specialized software. With respect to quantitative analysis, the measurement of chromatographic 
peak areas is more accurate when compared to a MS signal-based technique, which may suffer 
from differences in ionization efficiencies for different peptides and ion suppression from 
impurities. 
Plots for reaction times between 1 and 5 min were obtained to confirm the observed %A
0
FR 
differences. These time course plots can also be used to rule out abnormal %A
0
FR differences 
potentially caused by experimental errors at specific time points. The A
0
FR time course plots of 
all identified lysine-containing peptides are shown in the Supplementary Material (Figure S1). 
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The %RSD values from three independent experiments are shown as error bars in each plot. 
Many of the peptides containing overlapping sequences (e.g. LC 108-125 and LC 123-142, LC 
39-60 and LC 42-60, HC 68-76 and HC 75-87, HC 278-288 and HC 280-293, HC 328-338 and 
HC 332-343) showed similar trends. The results from these overlapping peptides offered an 
additional opportunity to confirm our results.  
 
The Effect of PS-20 on mAb1 Structure  
PS-20 is a non-ionic surfactant commonly used as an excipient in therapeutic protein products. It 
is usually present at 0.01%-0.1% (w/w) to protect proteins from surface adsorption, aggregation 
and denaturation caused by sheer forces during shipping
34,35,42,43
. The interaction between PS-20 
and proteins has been studied by various techniques such as CD spectroscopy, isothermal 
titration calorimetry (ITC) and tryptophan fluorescence
44-47
. These experiments demonstrated 
that PS-20 interacted with proteins in a non-specific manner and that the interaction was 
generally weak. On the other hand, the effect of PS-20 on protein stability was apparently 
dependent on the PS-20 to protein ratio. The exact effect of PS-20 as a protein protector varies 
from protein to protein. Deechongkit et al. 
44
 demonstrated a PS-20-dependent global protein 
structural change for an alpha helix-rich monomeric protein (Darbepoetin alfa). However, more 
specific information on the peptide and/or amino acid level was not obtained due to the limited 
resolution of the analytical methods (CD and tryptophan fluorescence). Previous findings 
indicated that the interaction between PS-20 and IgG is negligible
46,47
. Here, we will apply 
fluorescent surface lysine labeling to study the interaction between PS-20 and mAb1 at various 
PS-20 to protein ratios.  
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Our mAb1 (5 mg/mL) was incubated with 0.01%-0.5% PS-20 such that the protein-to-PS-20 
ratio was approximately 1:3, 1:10, 1:30 and 1:100. Both the protein concentration and PS-20 
concentration range are typical for therapeutic protein formulations. PS-20 does not affect the 
chemical reactions that are important for our method and was, therefore, not removed before 
fluorescent labeling. The protein sample containing PS-20 was subjected to fluorescent labeling, 
denaturation and digestion according to the protocols described in the experimental section 
above. The protein-to-dye ratio was 1:100 and five time points for each sample were collected 
for 1-5 min of reaction time. The A
0
FR was calculated as described above. Three independent 
samples were prepared for each of the experiments shown below.  
The normalized fluorescent peak areas (A
0
FR) obtained from various PS-20 concentrations are 
compared in Figure 7. Overall, the fluorescent labeling does not change significantly for protein-
to-PS-20 ratios between 1:3 and 1:100 while some difference were noted for mAb1 in the 
absence and presence of PS-20 (e.g., peptides 11, 16, 24 and 33).  There is no clear PS-20 
concentration-related trend observed in this experiment. These data suggest that the interaction 
between PS-20 and mAb1 is comparable for protein to PS-20 ratios between 1:3 and 1:100. This 
observation is different compared to that made for Darbepeotin alpha, where a protein-to-PS-20 
ratio of 1:15 had the strongest stabilizing effect
44
. The difference could be due to the fact that 
Darbepeotin is mainly composed of α-helix while mAb1 contains mainly β-sheets. Previous 
reports found that only monomeric PS-20 rather than micelles are responsible for the interaction 
between PS-20 and proteins
44
. Since the PS-20 concentrations used in our experiments were all 
above the critical micelle concentration (CMC), the concentration of PS-20 monomers was 
relatively small and constant while the concentration of PS-20 micelles increased with PS-20 
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concentration.  The absence of a clear trend between protein to PS-20 ratios of 1:3 and 1:100 
would argue against a strong interaction of PS-20 micelles with our mAb1. 
 
 
 
Figure 7. Bar chart showing the normalized fluorescence peak areas of labeled mAb1 peptides in 
the presence of 0-0.5% PS-20. The protein concentration was constant at 5 mg/mL. The peptides 
are numbered according to their retention times. The error bar shows the RSD% values from 
three experiments. 
 
The A
0
FR for mAb1 peptides in the presence and absence of PS-20 were compared. The PS-20 
concentration representatively compared here was 0.01% since this is a typical concentration 
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used in formulations for biotherapeutics. The lysine residues with an increased A
0
FR were 
marked with magenta on the homology structure in Figure 8.  No lysine residues were observed 
with a decreased level of fluorescence labeling. Lysine residues with an unchanged level of 
fluorescence labeling were not colored. Since PS-20 is a non-ionic surfactant, the interaction 
between PS-20 and the mAb1 is mainly between the hydrophobic regions of the protein and the 
hydrocarbon chains of PS-20
45
.  The hydrophobic residues on mAb1, namely V, I, L, M, F and 
W, are colored orange for comparison in the same Figure 8. Most of the lysine residues with an 
increased level of fluorescence labeling are located in proximity to the hydrophobic pockets of 
mAb1. Among these, three lysine residues are located in the VL domain, two in the VH domain, 
two in the CL domain, one in the CH1 domain and two in the CH3 domain. The locations of 
these lysine residues spread across the entire IgG1 structure indicating that the interaction 
between PS-20 and mAb1 is not specific.  The increased level of fluorescence labeling suggests 
that the presence of PS-20 increased the reactivity of the lysine residue under consideration. This 
observation may due to 1. an increased solvent accessibility of the lysines in these regions as PS-
20 stabilizes the interaction between these hydrophobic region and the aqueous environment. 2. 
an increased local dye concentration in the non-polar phase of the PS-20 layer, leading to an 
increased local dye-to-protein ratio in these hydrophobic regions. The lysine reaction time 
courses, indicating a PS-20-dependent increase of fluorescence labeling, are shown on the 
bottom of Figure 8. Only the peptides with fluorescence labeling efficiency difference greater 
than 30% were shown in the figure. Overall, the differences between the fluorescence labeling in 
the presence and absence of PS-20 is relatively small.  The differences in fluorescence labeling 
were mostly <30% at the end of the 5 min reaction time and differences were generally not 
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apparent before 3 min of reaction time.  These growing differences may indicate that the 
interaction between PS-20 and protein affects the protein dynamics in these regions. 
 
Figure 8. Homology structure of mAb1 showing hydrophobic residues and the lysine residues 
with increased levels of fluorescence labeling in the presence of 0.01% PS-20. The hydrophobic 
residues are colored orange. Lysine residues with increased levels of fluorescence labeling ware 
colored magenta. Lysine residues with changed labeling levels are highlighted in the homology 
structure (only half of the lysines are highlighted due to structural symmetry). Plots of time 
K251&K253
(HC)
K63&K65
(HC)
K38,K41&K44
(LC)
K187&K189
(LC)
K227
(HC)
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courses showing peptides with differences in fluorescence labeling are shown on the bottom. The 
error bar shows the RSD% values from three experiments. 
 Overall, our results are consistent with the notion that the interaction between PS-20 and mAb1 
is generally weak.  Most of the lysine residues did not show any significant differences in 
fluorescence labeling. For those lysine residues which showed a difference, this difference was 
<30% (RSD% < 10%). The presence of PS-20 increased the fluorescence labeling of several 
lysine residues on the mAb1. These lysine residues are located near regions of relatively high 
hydrophobicity. A protein-to-PS-20 ratio ranging from 1:3 to 1:100 does not appear to affect the 
interaction of PS-20 with our mAb1. 
The sample preparation and analysis requires no specialized instruments, while the data analysis 
can be done automatically in batch mode. The high throughput nature of this method makes it a 
very useful screening tool.  
 
CONCLUSIONS 
The surface lysine fluorescent labeling method described here utilizes a fluorescent dye to probe 
the solvent accessibility of protein surface lysines. The solvent accessibility changes can 
represent protein structural and dynamic differences. We demonstrated that this method is 
capable of detecting structural changes on a monoclonal antibody. The introduction of 
fluorescent labeling makes it possible to detect changes in lysine reactivity, which correlates with 
solvent accessibility. The fluorescence detection is sensitive with a wide dynamic range. This 
method can be used to screen multiple different excipients to get an overview of their interaction 
with a protein within a few days. Alternatively, when a conformational difference between two 
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samples is suspected, this method can rapidly provide results to guide a decision on whether to 
invest resources to analyze these differences by more sophisticated techniques.  Once a 
difference in fluorescence labeling has been confirmed by chromatography, an HPLC-MS/MS 
experiment can be performed to identify the exact location of this difference. The fluorescent dye 
used here does not interfere with the MS signal and the data analysis step can be achieved with 
commonly used software such as Mascot (Matrix Science) or Proteome Discoverer (Thermo 
Scientific). The chromatography peak area based calculation is reproducible and automatable. 
When studying the comparability of multiple samples, this method can potentially be used in a 
high throughput manner screening for structural differences between samples without the need of 
extensive data mining.  
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SUPPLIMENTARY DATA 
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FIGURE CAPTIONS FOR SUPPLIMETRAY DTA 
Figure S1. Normalized FL peak area of lysine-containing peptides from native and 
deglycosylated mAb-1 with surface lysine fluorescent labeling with 1-5 min reaction time. The 
error bar represents the standard deviation calculation from three repetitive experiments. The FL 
peak area of each peak was normalized to the protein concentration of the sample. 
Figure S2. Normalized FL peak area of lysine-containing peptides from mAb-1 in buffer and 
0.01% PS-20 with 1-5 min reaction time. Only data from the peptides with a significant 
fluorescent labeling level difference were shown. The error bar represents the standard deviation 
calculation from three repetitive experiments. The FL peak area of each peak was normalized to 
the protein concentration of the sample. 
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Figure S1 
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